GelVac(TM) Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes Preclinical Toxicolo...(rrington also manufactures andmarkets co...)

Date:1/15/2008

rrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.

'/>"/>

SOURCE Carrington Laboratories, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program
2. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
3. Aktiv-Dry Awarded Research Grant to Explore Inhalable siRNA Dry Powder Targeting RSV
4. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
5. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
6. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
7. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
8. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
9. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
10. Vical Presentation at Military Pandemic Influenza Workshop
11. Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated